Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review.

We aimed to investigate the role of anti-vascular endothelial growth factor (VEGF) agents, including tyrosine-kinase inhibitors or monoclonal anti-bodies, in the treatment of elderly hepatocellular carcinoma (HCC) patients.